Page last updated: 2024-12-07

marimastat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Marimastat is a synthetic hydroxamate-based matrix metalloproteinase (MMP) inhibitor. It was initially developed for the treatment of cancer, targeting MMPs that are involved in tumor growth and metastasis. Marimastat is a potent inhibitor of several MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13. However, its development as a cancer drug was halted due to significant side effects, including musculoskeletal pain and muscle weakness. Despite this, marimastat remains a valuable tool for researchers studying MMPs and their role in various biological processes. It is still used in preclinical research to investigate the role of MMPs in various diseases, including cancer, arthritis, and cardiovascular disease.'

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID119031
CHEMBL ID279785
CHEBI ID50662
SCHEMBL ID34033
MeSH IDM0263481

Synonyms (70)

Synonym
butaneamide,2-dimethyl-1-[(methylamino)carbonyl]propyl]- n1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
marimastat
bb2516
nsc689451
marimastat (usan/inn)
D03795 ,
marimastat [usan]
(2s,3r)-3-(((1s)-2,2-dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid
butanediamide, n(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2s-(n(sup 4)(r*),2r*,3s*))-
bb-2516 ,
(2s,3r)-3-(((1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid
butanediamide, n4-((1s)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
butanediamide, n4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s-(n4(r*),2r*,3s*))-
(2s,3r)-n~4~-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n~1~,2-dihydroxy-3-(2-methylpropyl)butanediamide
DB00786
bb 2516
nsc-689451
154039-60-8
nsc719333
nsc-719333
CHEBI:50662 ,
(2s,3r)-n(4)-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-n(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
gi 5712
kb-r 8898
CHEMBL279785 ,
ta 2516
gi-5712
ta-2516
bdbm50063917
cid_119031
(2r,3s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-n',3-dihydroxy-2-(2-methylpropyl)butanediamide
d5eqv23tds ,
nsc 719333
unii-d5eqv23tds
marimastat [usan:inn:ban]
smr002530328
MLS003899230
S7156
(2s,3r)-n-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n',2-dihydroxy-3-(2-methylpropyl)butanediamide
gtpl5220
MLS006010669
SCHEMBL34033
3HY7
marimastat [mi]
marimastat [who-dd]
marimastat [inn]
marimastat [mart.]
(2s,3r)-3-[[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]carbamoyl]-2-hydroxy-5-methylhexanohydroxamic acid
butanediamide, n(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s-(n4(r*),2r*,3s*))-
CS-3456
butanediamide, n4-[(1s)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-n1,2-dihydroxy-3-(2-methylpropyl)-, (2s,3r)-
(2s,3r)-n4-[(1s)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-n1,2-dihydroxy-3-(2-methylpropyl)butanediamide
marimistat
HY-12169
AKOS024457206
DTXSID20165524
EX-A643
marimastat, >=98% (hplc)
J-009063
(2r,3s)-n1-((s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-n4,3-dihydroxy-2-isobutylsuccinamide
marimastat - cas 154039-60-8
bb2516;ta2516
marimastat (bb-2516)
Q6763659
AMY6910
CCG-267821
(2s,3r)-n'-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-n,2-dihydroxy-3-(2-methylpropyl)butanediamide
AS-57129
(2r)-n-[(1s)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-2-[(1s)-1-hydroxy-2-(hydroxyamino)-2-oxo-ethyl]-4-methyl-pentanamide
AC-35828

Research Excerpts

Overview

Marimastat is a potent inhibitor of matrix metalloproteinases and in preclinical studies enhances the anti-tumor activity of certain chemotherapeutics. It seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma.

ExcerptReferenceRelevance
"Marimastat is a metalloproteinase inhibitor that was tested in clinical trials of cancer."( The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus.
Bulska, E; Kaczmarek, L; Khomiak, D; Konopka, A; Pijet, B; Pikul, S; Rejmak, E; Stefaniuk, M, 2020
)
1.55
"Marimastat seems to be a candidate for the prevention of peritoneal spread of gastric carcinoma."( Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice.
Fujii, M; Igarashi, N; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Okada, Y; Otani, Y; Wada, N; Yokoyama, T; Yoshimizu, N, 2002
)
1.31
"Marimastat is a synthetic MMPI which has been investigated in clinical studies of patients with advanced cancers."( Effect of marimastat on serum tumour markers in patients with colorectal cancer.
King, J; Morris, DL; North, H, 2000
)
1.43
"Marimastat is a potent inhibitor of matrix metalloproteinases and in preclinical studies enhances the anti-tumor activity of certain chemotherapeutics. "( A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
Goodin, S; Gounder, M; Lin, Y; Medina, M; Much, J; Musanti, R; Orlando, T; Pennick, M; Rubin, E; Shih, W; Toppmeyer, DL; Vyas, V, 2003
)
2.01
"Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that inhibits almost all major MMPs, key enzymes in gastric cancer invasion and metastasis. "( Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition.
Fujii, M; Furukawa, T; Kameyama, K; Kimata, M; Kitajima, M; Kubota, T; Kumai, K; Minagawa, A; Okada, Y; Otani, Y; Saikawa, Y; Wada, N; Yoshida, M; Yoshimizu, N, 2003
)
1.76
"Marimastat is an orally bioavailable inhibitor of matrix metalloproteinases. "( Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG, 2005
)
2.02
"Marimastat is a matrix metalloproteinase inhibitor, whose main toxicity is musculoskeletal."( Gastric cancer. Treatment of advanced disease and new drugs.
Caponigro, F; Facchini, G; Iaffaioli, RV; Nasti, G, 2005
)
1.05
"Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. "( Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
Baillet, M; Barker, K; Berrington, A; Bleiberg, H; Brown, PD; Daniel, F; Johnson, PW; Lynch, KP; Mansi, JL; Millar, AW; Neoptolemos, JP; Primrose, JN; Seymour, M; Van Belle, S, 1999
)
3.19

Effects

Marimastat has only limited activity in patients with metastatic malignant melanoma. It also has collagenase- and angiogenesis-inhibiting properties.

ExcerptReferenceRelevance
"Marimastat has only limited activity in patients with metastatic malignant melanoma. "( Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
Belanger, K; Bodurth, A; Eisenhauer, E; Lohmann, R; Quirt, I; Rusthoven, J; Stewar, W; Wainman, N; Young, V, 2002
)
2.09
"Marimastat also has collagenase- and angiogenesis-inhibiting properties."( Marimastat: BB 2516, TA 2516.
, 2003
)
2.48

Treatment

Marimastat-treated animals demonstrated significantly attenuated liver injury and inflammation but a 25% increase in collagen deposition. Marimast at treatment allowed for an enrichment of our cultures in neuronal cells, inducing NPs to generate higher percentage of neurons and a lower percentage of astrocytes.

ExcerptReferenceRelevance
"Marimastat-treated animals demonstrated significantly attenuated liver injury and inflammation but a 25% increase in collagen deposition."( Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.
de Meijer, VE; Le, HD; Meisel, JA; Nosé, V; Popov, Y; Puder, M; Schuppan, D; Sverdlov, DY, 2010
)
1.08
"In marimastat-treated or vehicle-control groups, three possible functional biomarkers were assessed: paw volume (PV), landing foot splay separation (LFSS), and rotarod performance (n=6 rats/group for each endpoint)."( Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors.
Fryer, RM; Harrison, PC; Li, J; Mazurek, SG; Muthukumarana, AC; Nabozny, GH; Reinhart, GA,
)
0.65
"Marimastat treatment allowed for an enrichment of our cultures in neuronal cells, inducing NPs to generate higher percentage of neurons and a lower percentage of astrocytes, possibly affecting NP commitment."( The matrix metalloproteinase inhibitor marimastat promotes neural progenitor cell differentiation into neurons by gelatinase-independent TIMP-2-dependent mechanisms.
Ajmone-Cat, MA; Biagioni, S; Cacci, E; Caramanica, P; Mannello, F; Medda, V; Minghetti, L; Pafumi, I; Sinno, M; Tonti, G, 2013
)
1.38
"Marimastat-treated rats exhibited various clinical signs, including compromised ability to rest on their hind feet, high-stepping gait, reluctance or inability to move, and hind paw swelling. "( Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.
Baragi, V; Cody, T; Devalaraja, R; Kaldjian, E; Lesch, C; Qiu, L; Renkiewicz, R; Sun, X; Welgus, H, 2003
)
2.01
"Marimastat treatment was associated with the development of musculoskeletal pain and inflammation."( Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
Baillet, M; Bramhall, SR; Brown, PD; Fielding, JW; Hallissey, MT; Hawkins, RE; Maughan, T; McCulloch, P; Scholefield, J; Stuart, RC; Tierney, G; Whiting, J, 2002
)
2.48
"Treatment with marimastat, starting at 3 years of age, resulted in rapid resolution of pain and gradual healing of bony destruction, associated with regression of the intraosseous arteriovenous shunts."( Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child.
Burrows, PE; Fishman, SJ; Folkman, J; Klement, GL; Mulliken, JB, 2009
)
0.69
"Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life."( Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Orga
Bezjak, A; Debruyne, C; Giaccone, G; Hirsh, V; Krzakowski, M; Lamont, A; Martins, H; Rubin, S; Sadura, A; Seymour, L; Shepherd, FA; Smylie, M; Zee, B, 2002
)
0.9

Toxicity

ExcerptReferenceRelevance
"The ability of two peptidomimetic hydroxamate metalloproteinase inhibitors, Batimastat and Marimastat, to abrogate toxic and proteinase activities of the venom of Echis ocellatus from Cameroon and Ghana was assessed."( Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom.
Arias, AS; Gutiérrez, JM; Rucavado, A, 2017
)
0.68

Compound-Compound Interactions

ExcerptReferenceRelevance
" A phase I study was initiated to determine whether conventional doses of carboplatin and paclitaxel are tolerated when combined with marimastat and to assess the influence of marimastat on paclitaxel pharmacokinetics."( Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG, 2005
)
0.78
" Study of this drug combination in the adjuvant setting should be considered if tissue inhibition of matrix metalloproteinase activity can first be shown."( Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG, 2005
)
0.57

Bioavailability

Marimastat (BB-2516) is the first orally bioavailable matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology.

ExcerptReferenceRelevance
"Marimastat was well absorbed from the gastrointestinal tract, with high levels of the study drug detected in plasma within hours after drug administration."( Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
Chiodo, TA; Dickson, R; Hawkins, MJ; Johnson, M; Marshall, J; Ness, E; Rasmussen, HS; Sale, M; Steen, V; Torri, J; Wojtowicz-Praga, S, 1998
)
2.08
" It has excellent bioavailability and has completed phase I and II trials."( Marimastat (BB2516): current status of development.
Steward, WP, 1999
)
1.75
" In addition, the bioavailability and effect of marimastat on a range of MMPs were assessed in-vitro."( The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.
Bhogal, R; Bird, J; Brampton, C; Chander, C; Parsons, ME; Sykes, AP; Whelan, C, 1999
)
0.56
"In this study we have confirmed that marimastat is a broad spectrum MMPI with a bioavailability of 5%."( The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.
Bhogal, R; Bird, J; Brampton, C; Chander, C; Parsons, ME; Sykes, AP; Whelan, C, 1999
)
0.58
"Marimastat (BB-2516) is the first orally bioavailable matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology."( Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
Steward, WP; Thomas, AL, 2000
)
3.19
" The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail."( Development of matrix metalloproteinase inhibitors in cancer therapy.
Eckhardt, SG; Hidalgo, M, 2001
)
0.53
" Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models."( Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK, 2002
)
0.31
"Marimastat is an orally bioavailable inhibitor of matrix metalloproteinases."( Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG, 2005
)
2.02
" Since the discovery of anti-TNF-alpha biologicals, much efforts have gone into developing an orally bioavailable small size TNF-alpha antagonist."( Current perspective of TACE inhibitors: a review.
DasGupta, S; Giridhar, R; Murumkar, PR; Yadav, MR, 2009
)
0.35

Dosage Studied

Small but reversible elevations in liver transaminases were noted with repeat dosing of marimastat. Most significant of these occurred at a dose of 200 mg twice daily. Proportion of patients with BE or PBE was higher with twice daily dosing.

ExcerptRelevanceReference
" Small but reversible elevations in liver transaminases were noted with repeat dosing of marimastat, the most significant of these occurring at a dose of 200 mg twice daily."( Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
Brown, PD; Cornish, AG; Galloway, WA; Lenehan, TJ; Lynch, KP; Millar, AW; Moore, J, 1998
)
0.74
" It has a terminal elimination half-life of 8-10 h which would support twice daily dosing in further clinical trials."( Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
Brown, PD; Cornish, AG; Galloway, WA; Lenehan, TJ; Lynch, KP; Millar, AW; Moore, J, 1998
)
0.52
" An analogue (12c) possessing an alpha-cyclopentyl group is a potent broad spectrum inhibitor that displays high and sustained blood levels following oral dosing in both the rat and marmoset ex-vivo bioassays."( The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
Beckett, RP; Bellamy, CL; Corkill, DJ; Cossins, J; Courtney, PF; Davidson, AH; Davies, SJ; Drummond, AH; Helfrich, K; Lewis, CN; Mangan, M; Martin, FM; Miller, K; Nayee, P; Pratt, LM; Ricketts, ML; Thomas, W; Todd, RS; Whittaker, M, 1998
)
0.3
" Measurement of the rate of change of circulating tumour antigens was used for evaluating biological activity and defining optimum dosage in the early clinical trials of marimastat."( Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
Bawden, LJ; Bone, EA; Collins, HM; Hawkins, K; Morris, TM; Watson, SA, 1999
)
0.78
"Rats were dosed (by mouth) for 7 days (b."( The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.
Bhogal, R; Bird, J; Brampton, C; Chander, C; Parsons, ME; Sykes, AP; Whelan, C, 1999
)
0.3
" This study compared local delivery of marimastat by regional limb perfusion (RLP) to systemic intravenous bolus dosing (SIVB), and established whether RLP results in local lamellar drug delivery."( Regional intravenous limb perfusion compared to systemic intravenous administration for marimastat delivery to equine lamellar tissue.
Allavena, RE; Collins, SN; Medina Torres, CE; Mills, PC; Pollitt, CC; Underwood, C; Van Eps, AW, 2015
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
matrix metalloproteinase inhibitornull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, A disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)IC50 (µMol)0.10600.10600.10600.1060AID977608
Chain A, Catalytic Domain of ADAMTS-5Homo sapiens (human)IC50 (µMol)0.10600.10600.10600.1060AID977608
Chain A, A disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)IC50 (µMol)0.10600.10600.10600.1060AID977608
ADAM10Homo sapiens (human)IC50 (µMol)0.04820.03585.50189.0460AID743254; AID743259
disintegrin and metalloproteinase domain-containing protein 17 isoform 1 preproproteinHomo sapiens (human)IC50 (µMol)0.01840.01153.04769.1060AID743253; AID743260
Matrix metalloproteinase-20Homo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID1274674
A disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)IC50 (µMol)10.00000.10003.526710.0000AID1274708
Tumor necrosis factorHomo sapiens (human)IC50 (µMol)1.00100.20000.67911.3000AID210150
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)0.83580.00020.850210.0000AID104554; AID104556; AID104923; AID108731; AID108749; AID108751; AID108758; AID108766; AID108894; AID109078; AID1274664; AID1863874
Interstitial collagenaseHomo sapiens (human)Ki0.00100.00030.49487.0000AID108931; AID108932; AID108935; AID109221
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.71670.00001.284810.0000AID104711; AID104713; AID104925; AID107159; AID107160; AID107168; AID107172; AID107333; AID109580; AID1274665; AID1574651; AID1607846; AID1863875; AID1875285
72 kDa type IV collagenaseHomo sapiens (human)Ki0.00060.00000.34663.0000AID107344
Stromelysin-1Homo sapiens (human)IC50 (µMol)1.05290.00001.148410.0000AID104747; AID104749; AID104927; AID107358; AID107502; AID107514; AID107675; AID1274648; AID1863876; AID1875284
Stromelysin-1Homo sapiens (human)Ki0.04480.00030.54258.0000AID107654; AID107655; AID107657; AID107685
MatrilysinHomo sapiens (human)IC50 (µMol)2.00900.00142.085910.0000AID104928; AID107840; AID1274667; AID1863877; AID1875283
Stromelysin-2Homo sapiens (human)IC50 (µMol)10.00000.00052.875410.0000AID1274669
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)10.00000.00002.800510.0000AID1274675
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)1.08180.00000.705310.0000AID104919; AID108007; AID108140; AID108147; AID108303; AID1274668; AID1574652; AID1607847; AID1863879; AID1875282
Matrix metalloproteinase-9Homo sapiens (human)Ki0.00770.00020.12810.8000AID108162; AID108176; AID108177
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)2.00130.00000.927210.0000AID104912; AID107849; AID107991; AID1274666; AID1863878
Delta-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00030.38877.0000AID1574652
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.600310.0000AID1274707
Macrophage metalloelastaseHomo sapiens (human)IC50 (µMol)5.00250.00022.721710.0000AID1274670; AID1863880
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00310.00030.71237.0700AID1574652
Collagenase 3Homo sapiens (human)IC50 (µMol)0.01620.00000.767510.0000AID104707; AID104708; AID109264; AID109377; AID109382; AID109384; AID109417; AID1863881; AID1875281
Matrix metalloproteinase-14Homo sapiens (human)IC50 (µMol)3.33450.00030.718210.0000AID1274671; AID1863882; AID220527
Matrix metalloproteinase-15Homo sapiens (human)IC50 (µMol)10.00000.00603.337310.0000AID1274672
Matrix metalloproteinase-16Homo sapiens (human)IC50 (µMol)10.00000.00802.193410.0000AID1274673
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)IC50 (µMol)5.66790.00021.014010.0000AID1274707; AID215604; AID347023
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Ki0.00240.00010.50303.7000AID210018; AID215264; AID215597
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.630610.0000AID1274707
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00061.525710.0000AID1274707
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.747210.0000AID1274707
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)IC50 (µMol)0.00310.00202.123310.0000AID1574652
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID1274707
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID1274707
Matrix metalloproteinase-25Homo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID1274676
Matrix metalloproteinase-26Homo sapiens (human)IC50 (µMol)10.00000.01703.344710.0000AID1274677
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)10.00000.00071.741110.0000AID1274707
A disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)IC50 (µMol)10.00000.50004.475010.0000AID1274709
Matrix metalloproteinase-24Homo sapiens (human)IC50 (µMol)10.000010.000010.000010.0000AID1274675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)Activity0.00290.00290.27550.8000AID108728
72 kDa type IV collagenaseHomo sapiens (human)Activity0.00080.00030.00050.0008AID109578
Collagenase 3Homo sapiens (human)Activity0.00200.00050.00100.0020AID109247
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (341)

Processvia Protein(s)Taxonomy
proteolysisMatrix metalloproteinase-20Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-20Homo sapiens (human)
protein catabolic processMatrix metalloproteinase-20Homo sapiens (human)
regulation of enamel mineralizationMatrix metalloproteinase-20Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-20Homo sapiens (human)
amelogenesisMatrix metalloproteinase-20Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-20Homo sapiens (human)
skeletal system developmentA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
proteolysisA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrix disassemblyA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrix organizationA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-33 productionTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of signaling receptor activityTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of synoviocyte proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of I-kappaB phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
response to hypoxiaTumor necrosis factorHomo sapiens (human)
microglial cell activationTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of protein phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of endothelial cell proliferationTumor necrosis factorHomo sapiens (human)
negative regulation of L-glutamate import across plasma membraneTumor necrosis factorHomo sapiens (human)
macrophage activation involved in immune responseTumor necrosis factorHomo sapiens (human)
chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
leukocyte migration involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
regulation of immunoglobulin productionTumor necrosis factorHomo sapiens (human)
negative regulation of cytokine production involved in immune responseTumor necrosis factorHomo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinTumor necrosis factorHomo sapiens (human)
skeletal muscle contractionTumor necrosis factorHomo sapiens (human)
negative regulation of systemic arterial blood pressureTumor necrosis factorHomo sapiens (human)
glucose metabolic processTumor necrosis factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
inflammatory responseTumor necrosis factorHomo sapiens (human)
humoral immune responseTumor necrosis factorHomo sapiens (human)
JNK cascadeTumor necrosis factorHomo sapiens (human)
circadian rhythmTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsTumor necrosis factorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTumor necrosis factorHomo sapiens (human)
response to xenobiotic stimulusTumor necrosis factorHomo sapiens (human)
response to virusTumor necrosis factorHomo sapiens (human)
response to salt stressTumor necrosis factorHomo sapiens (human)
response to fructoseTumor necrosis factorHomo sapiens (human)
negative regulation of heart rateTumor necrosis factorHomo sapiens (human)
vascular endothelial growth factor productionTumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of lipid storageTumor necrosis factorHomo sapiens (human)
response to activityTumor necrosis factorHomo sapiens (human)
regulation of metabolic processTumor necrosis factorHomo sapiens (human)
calcium-mediated signalingTumor necrosis factorHomo sapiens (human)
extracellular matrix organizationTumor necrosis factorHomo sapiens (human)
osteoclast differentiationTumor necrosis factorHomo sapiens (human)
sequestering of triglycerideTumor necrosis factorHomo sapiens (human)
cortical actin cytoskeleton organizationTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex assemblyTumor necrosis factorHomo sapiens (human)
positive regulation of fever generationTumor necrosis factorHomo sapiens (human)
negative regulation of myelinationTumor necrosis factorHomo sapiens (human)
response to nutrient levelsTumor necrosis factorHomo sapiens (human)
negative regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of fractalkine productionTumor necrosis factorHomo sapiens (human)
positive regulation of type II interferon productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-1 beta productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-18 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationTumor necrosis factorHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTumor necrosis factorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTumor necrosis factorHomo sapiens (human)
toll-like receptor 3 signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityTumor necrosis factorHomo sapiens (human)
response to isolation stressTumor necrosis factorHomo sapiens (human)
response to macrophage colony-stimulating factorTumor necrosis factorHomo sapiens (human)
vasodilationTumor necrosis factorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTumor necrosis factorHomo sapiens (human)
positive regulation of apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of programmed cell deathTumor necrosis factorHomo sapiens (human)
regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
negative regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of JUN kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of neuron apoptotic processTumor necrosis factorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationTumor necrosis factorHomo sapiens (human)
negative regulation of viral genome replicationTumor necrosis factorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processTumor necrosis factorHomo sapiens (human)
response to ethanolTumor necrosis factorHomo sapiens (human)
regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of myoblast differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of osteoblast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of osteoclast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of protein catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of action potentialTumor necrosis factorHomo sapiens (human)
positive regulation of cell adhesionTumor necrosis factorHomo sapiens (human)
positive regulation of mitotic nuclear divisionTumor necrosis factorHomo sapiens (human)
negative regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of mitotic cell cycleTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of translational initiation by ironTumor necrosis factorHomo sapiens (human)
negative regulation of glucose importTumor necrosis factorHomo sapiens (human)
positive regulation of JNK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTumor necrosis factorHomo sapiens (human)
astrocyte activationTumor necrosis factorHomo sapiens (human)
embryonic digestive tract developmentTumor necrosis factorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of neurogenesisTumor necrosis factorHomo sapiens (human)
regulation of insulin secretionTumor necrosis factorHomo sapiens (human)
positive regulation of synaptic transmissionTumor necrosis factorHomo sapiens (human)
regulation of synapse organizationTumor necrosis factorHomo sapiens (human)
defense response to Gram-positive bacteriumTumor necrosis factorHomo sapiens (human)
cognitionTumor necrosis factorHomo sapiens (human)
leukocyte tethering or rollingTumor necrosis factorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTumor necrosis factorHomo sapiens (human)
negative regulation of lipid catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of protein transportTumor necrosis factorHomo sapiens (human)
response to glucocorticoidTumor necrosis factorHomo sapiens (human)
positive regulation of hair follicle developmentTumor necrosis factorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
regulation of synaptic transmission, glutamatergicTumor necrosis factorHomo sapiens (human)
positive regulation of glial cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of vitamin D biosynthetic processTumor necrosis factorHomo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activityTumor necrosis factorHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
regulation of branching involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
negative regulation of vascular wound healingTumor necrosis factorHomo sapiens (human)
negative regulation of branching involved in lung morphogenesisTumor necrosis factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTumor necrosis factorHomo sapiens (human)
cellular response to lipopolysaccharideTumor necrosis factorHomo sapiens (human)
cellular response to amino acid stimulusTumor necrosis factorHomo sapiens (human)
cellular response to retinoic acidTumor necrosis factorHomo sapiens (human)
cellular response to nicotineTumor necrosis factorHomo sapiens (human)
cellular response to type II interferonTumor necrosis factorHomo sapiens (human)
cellular response to ionizing radiationTumor necrosis factorHomo sapiens (human)
positive regulation of mononuclear cell migrationTumor necrosis factorHomo sapiens (human)
positive regulation of podosome assemblyTumor necrosis factorHomo sapiens (human)
endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
negative regulation of oxidative phosphorylationTumor necrosis factorHomo sapiens (human)
inflammatory response to woundingTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to toxic substanceTumor necrosis factorHomo sapiens (human)
liver regenerationTumor necrosis factorHomo sapiens (human)
necroptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of bile acid secretionTumor necrosis factorHomo sapiens (human)
antiviral innate immune responseTumor necrosis factorHomo sapiens (human)
response to Gram-negative bacteriumTumor necrosis factorHomo sapiens (human)
positive regulation of neuroinflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of amyloid-beta clearanceTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of amyloid-beta formationTumor necrosis factorHomo sapiens (human)
response to L-glutamateTumor necrosis factorHomo sapiens (human)
positive regulation of neutrophil activationTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
regulation of establishment of endothelial barrierTumor necrosis factorHomo sapiens (human)
negative regulation of bicellular tight junction assemblyTumor necrosis factorHomo sapiens (human)
cellular response to amyloid-betaTumor necrosis factorHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellTumor necrosis factorHomo sapiens (human)
regulation of membrane lipid metabolic processTumor necrosis factorHomo sapiens (human)
response to 3,3',5-triiodo-L-thyronineTumor necrosis factorHomo sapiens (human)
response to gold nanoparticleTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to cell surfaceTumor necrosis factorHomo sapiens (human)
positive regulation of blood microparticle formationTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionTumor necrosis factorHomo sapiens (human)
positive regulation of hepatocyte proliferationTumor necrosis factorHomo sapiens (human)
regulation of endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
regulation of reactive oxygen species metabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of DNA biosynthetic processTumor necrosis factorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTumor necrosis factorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
proteolysisStromelysin-2Homo sapiens (human)
extracellular matrix disassemblyStromelysin-2Homo sapiens (human)
collagen catabolic processStromelysin-2Homo sapiens (human)
extracellular matrix organizationStromelysin-2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIMacrophage metalloelastaseHomo sapiens (human)
proteolysisMacrophage metalloelastaseHomo sapiens (human)
protein import into nucleusMacrophage metalloelastaseHomo sapiens (human)
extracellular matrix disassemblyMacrophage metalloelastaseHomo sapiens (human)
collagen catabolic processMacrophage metalloelastaseHomo sapiens (human)
positive regulation of interferon-alpha productionMacrophage metalloelastaseHomo sapiens (human)
wound healing, spreading of epidermal cellsMacrophage metalloelastaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIMacrophage metalloelastaseHomo sapiens (human)
lung alveolus developmentMacrophage metalloelastaseHomo sapiens (human)
regulation of defense response to virus by hostMacrophage metalloelastaseHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in wound healingMacrophage metalloelastaseHomo sapiens (human)
elastin catabolic processMacrophage metalloelastaseHomo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayMacrophage metalloelastaseHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayMacrophage metalloelastaseHomo sapiens (human)
bronchiole developmentMacrophage metalloelastaseHomo sapiens (human)
cellular response to virusMacrophage metalloelastaseHomo sapiens (human)
response to amyloid-betaMacrophage metalloelastaseHomo sapiens (human)
negative regulation of endothelial cell-matrix adhesion via fibronectinMacrophage metalloelastaseHomo sapiens (human)
extracellular matrix organizationMacrophage metalloelastaseHomo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
angiogenesisMatrix metalloproteinase-14Homo sapiens (human)
ovarian follicle developmentMatrix metalloproteinase-14Homo sapiens (human)
response to hypoxiaMatrix metalloproteinase-14Homo sapiens (human)
endothelial cell proliferationMatrix metalloproteinase-14Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-14Homo sapiens (human)
response to oxidative stressMatrix metalloproteinase-14Homo sapiens (human)
male gonad developmentMatrix metalloproteinase-14Homo sapiens (human)
response to mechanical stimulusMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of myotube differentiationMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of protein processingMatrix metalloproteinase-14Homo sapiens (human)
response to organic cyclic compoundMatrix metalloproteinase-14Homo sapiens (human)
protein processingMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-14Homo sapiens (human)
protein catabolic processMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell growthMatrix metalloproteinase-14Homo sapiens (human)
lung developmentMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell migrationMatrix metalloproteinase-14Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-14Homo sapiens (human)
zymogen activationMatrix metalloproteinase-14Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-14Homo sapiens (human)
astrocyte cell migrationMatrix metalloproteinase-14Homo sapiens (human)
response to estrogenMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of B cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of Notch signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
branching morphogenesis of an epithelial tubeMatrix metalloproteinase-14Homo sapiens (human)
tissue remodelingMatrix metalloproteinase-14Homo sapiens (human)
cell motilityMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of focal adhesion assemblyMatrix metalloproteinase-14Homo sapiens (human)
head developmentMatrix metalloproteinase-14Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of GDF15-GFRAL signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
regulation of protein localization to plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of macrophage migrationMatrix metalloproteinase-14Homo sapiens (human)
response to odorantMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-14Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-15Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-15Homo sapiens (human)
response to estradiolMatrix metalloproteinase-15Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-15Homo sapiens (human)
protein modification processMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-15Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-16Homo sapiens (human)
proteolysisMatrix metalloproteinase-16Homo sapiens (human)
protein processingMatrix metalloproteinase-16Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-16Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-16Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-16Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-16Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-16Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-16Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisMatrix metalloproteinase-25Homo sapiens (human)
inflammatory responseMatrix metalloproteinase-25Homo sapiens (human)
hard palate developmentMatrix metalloproteinase-25Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-25Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-25Homo sapiens (human)
proteolysisMatrix metalloproteinase-26Homo sapiens (human)
negative regulation of inflammatory responseMatrix metalloproteinase-26Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-26Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-26Homo sapiens (human)
aortic valve morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
pulmonary valve morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
endocardial cushion morphogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
proteolysisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
myoblast fusionA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix disassemblyA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
defense response to bacteriumA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
negative regulation of cold-induced thermogenesisA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix organizationA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
proteolysisMatrix metalloproteinase-24Homo sapiens (human)
glial cell differentiationMatrix metalloproteinase-24Homo sapiens (human)
cell-cell adhesion mediated by cadherinMatrix metalloproteinase-24Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painMatrix metalloproteinase-24Homo sapiens (human)
neuronal stem cell population maintenanceMatrix metalloproteinase-24Homo sapiens (human)
cell-cell adhesion via plasma-membrane adhesion moleculesMatrix metalloproteinase-24Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-24Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-24Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
metalloendopeptidase activityMatrix metalloproteinase-20Homo sapiens (human)
protein bindingMatrix metalloproteinase-20Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-20Homo sapiens (human)
protease bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
metalloendopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
peptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
metallopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
zinc ion bindingA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
transcription cis-regulatory region bindingTumor necrosis factorHomo sapiens (human)
protease bindingTumor necrosis factorHomo sapiens (human)
cytokine activityTumor necrosis factorHomo sapiens (human)
tumor necrosis factor receptor bindingTumor necrosis factorHomo sapiens (human)
protein bindingTumor necrosis factorHomo sapiens (human)
death receptor agonist activityTumor necrosis factorHomo sapiens (human)
identical protein bindingTumor necrosis factorHomo sapiens (human)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
metalloendopeptidase activityStromelysin-2Homo sapiens (human)
serine-type endopeptidase activityStromelysin-2Homo sapiens (human)
zinc ion bindingStromelysin-2Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
core promoter sequence-specific DNA bindingMacrophage metalloelastaseHomo sapiens (human)
endopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
metalloendopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
serine-type endopeptidase activityMacrophage metalloelastaseHomo sapiens (human)
calcium ion bindingMacrophage metalloelastaseHomo sapiens (human)
collagen bindingMacrophage metalloelastaseHomo sapiens (human)
zinc ion bindingMacrophage metalloelastaseHomo sapiens (human)
sequence-specific DNA bindingMacrophage metalloelastaseHomo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
integrin bindingMatrix metalloproteinase-14Homo sapiens (human)
protein bindingMatrix metalloproteinase-14Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-14Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-15Homo sapiens (human)
protein bindingMatrix metalloproteinase-15Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-15Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-15Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-15Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-16Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-16Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-16Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-16Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingMatrix metalloproteinase-25Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-25Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-25Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-26Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-26Homo sapiens (human)
endopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
metalloendopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
integrin bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
heparin bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
peptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
metallopeptidase activityA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
zinc ion bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
identical protein bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrix bindingA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-24Homo sapiens (human)
enzyme activator activityMatrix metalloproteinase-24Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-24Homo sapiens (human)
cadherin bindingMatrix metalloproteinase-24Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
extracellular regionMatrix metalloproteinase-20Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-20Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-20Homo sapiens (human)
extracellular regionA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular spaceA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
nuclear speckA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
collagen-containing extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 4Homo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
phagocytic cupTumor necrosis factorHomo sapiens (human)
extracellular regionTumor necrosis factorHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
plasma membraneTumor necrosis factorHomo sapiens (human)
external side of plasma membraneTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
neuronal cell bodyTumor necrosis factorHomo sapiens (human)
membrane raftTumor necrosis factorHomo sapiens (human)
recycling endosomeTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
extracellular regionStromelysin-2Homo sapiens (human)
extracellular matrixStromelysin-2Homo sapiens (human)
extracellular spaceStromelysin-2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
extracellular regionMacrophage metalloelastaseHomo sapiens (human)
extracellular spaceMacrophage metalloelastaseHomo sapiens (human)
nucleusMacrophage metalloelastaseHomo sapiens (human)
cytoplasmMacrophage metalloelastaseHomo sapiens (human)
extracellular matrixMacrophage metalloelastaseHomo sapiens (human)
extracellular spaceMacrophage metalloelastaseHomo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
cytoplasmMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
nucleusMatrix metalloproteinase-14Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-14Homo sapiens (human)
cytosolMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
focal adhesionMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-14Homo sapiens (human)
cytoplasmic vesicleMatrix metalloproteinase-14Homo sapiens (human)
melanosomeMatrix metalloproteinase-14Homo sapiens (human)
macropinosomeMatrix metalloproteinase-14Homo sapiens (human)
intermediate filament cytoskeletonMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-15Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-15Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-15Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-16Homo sapiens (human)
plasma membraneMatrix metalloproteinase-16Homo sapiens (human)
cell surfaceMatrix metalloproteinase-16Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-16Homo sapiens (human)
plasma membraneMatrix metalloproteinase-16Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-16Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneMatrix metalloproteinase-25Homo sapiens (human)
membraneMatrix metalloproteinase-25Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-25Homo sapiens (human)
specific granule membraneMatrix metalloproteinase-25Homo sapiens (human)
side of membraneMatrix metalloproteinase-25Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-25Homo sapiens (human)
plasma membraneMatrix metalloproteinase-25Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-26Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-26Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
extracellular regionA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular spaceA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
endoplasmic reticulum lumenA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
collagen-containing extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
extracellular matrixA disintegrin and metalloproteinase with thrombospondin motifs 5Homo sapiens (human)
plasma membraneMatrix metalloproteinase-24Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-24Homo sapiens (human)
trans-Golgi network membraneMatrix metalloproteinase-24Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-24Homo sapiens (human)
plasma membraneMatrix metalloproteinase-24Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-24Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (168)

Assay IDTitleYearJournalArticle
AID1274671Inhibition of MMP14 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1875285Inhibition of MMP2 in human U2OS cells by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1607850Inhibition of MMP7 (unknown origin) using QF-24 as substrate preincubated for 1 hr followed by substrate addition and measured at 1 min interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID108931Inhibition of recombinant human matrix metalloprotease-12003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
AID1274707Inhibition of TACE (unknown origin) using Mca-Pro-Leu-Ala-Gln-Ala-Val-Dpa-Arg-Ser-Ser-Ser-Arg-NH2 as substrate2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID107849Inhibition of MMP-8 (matrix metalloprotease-8)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID107675Inhibition of Matrix metalloprotease-3 (MMP-3) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109384Inhibitory activity against matrix metalloprotease-13 (MMP13)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID11415Cmax after oral administration at 20 mpk in rats2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID1574652Inhibition of MMP9 (unknown origin) preincubated for 1 hr followed by (QF)-24 substrate addition measured at 1 min time interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID104923In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1274674Inhibition of MMP20 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID12715Bioavailability as oral AUC in rats1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID104927In vitro inhibitory activity against human recombinant matrix metalloprotease 31998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID108751Inhibitory activity against human Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
AID108007Activity against Matrix metalloprotease-9 (MMP-9).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1274665Inhibition of full length human recombinant MMP2 using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID215264Inhibitory potency against Tumor necrosis factor alpha converting enzyme (TACE)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
AID109221Inhibitory potency against Matrix metalloprotease-1 (MMP-1)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
AID13123Oral bioavailability in rat2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID152802Inhibitory concentration required against shedding of IL-1 RII from stimulated PBMCs2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID107685Inhibitory potency against Matrix metalloprotease-3 (MMP-3)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
AID1875283Inhibition of MMP7 in human U2OS cells by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID135561Percent inhibition against B16-F10 mouse melanoma tested in vivo at 30 mg/kg2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID104919Inhibition of matrix metalloprotease-91999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID109078In vitro selective inhibition against matrix metalloprotease-1 (MMP-1) using a fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID107160Inhibitory activity against human Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
AID104747Inhibition of matrix metalloprotease-31999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
AID108147Inhibitory activity against matrix metalloprotease-9 (MMP9)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID107840Inhibition of Matrix metalloprotease-7 (MMP-7) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID108728Inhibitory activity against human Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID209356Selective inhibition of the cellular TNF alpha release from LPS-stimulated THP-1 cells2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID107655Inhibition of recombinant human matrix metalloprotease-32003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID107991Inhibition of Matrix metalloprotease-8 (MMP-8) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID1863875Inhibition of MMP-2 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID108727Inhibition of matrix metalloprotease-1 (HFC)1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID347023Inhibition of TACE2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Current perspective of TACE inhibitors: a review.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1235682Inhibition of ADAM17 in human THP1 cells assessed as inhibition of LPS-stimulated TNFalpha cleavage at 10 uM after 1 hr by AlphaScreen assay relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
AID152804Inhibitory concentration required against shedding of L-Selectin from stimulated PBMCs2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1274666Inhibition of MMP8 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1863877Inhibition of MMP-7 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID109247Inhibitory activity against human Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID1265275Inhibition of recombinant Brugia malayi DPY-31 astacin domain expressed in Escherichia coli using Suc-Ala-Ala-Ala-pNA as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by microplate reader assay2015Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24
Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31.
AID1607849Inhibition of MMP13 (unknown origin) using QF-24 as substrate preincubated for 1 hr followed by substrate addition and measured at 1 min interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1574653Inhibition of MMP8 (unknown origin) preincubated for 1 hr followed by (QF)-24 substrate addition measured at 1 min time interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID108303In vitro selective inhibition against Matrix metalloprotease-9 (MMP-9) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID210018Inhibition of recombinant human TNF-alpha converting enzyme (TACE)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
AID12362Compound was tested for area under curve in rat1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1274664Inhibition of full length human recombinant MMP1 using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1274668Inhibition of full length human recombinant MMP9 using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID108140Inhibition of Matrix metalloprotease-92001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID109577Inhibition of matrix metalloprotease-2 (Gel.A)1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1607846Inhibition of MMP2 (unknown origin) using QF-24 as substrate preincubated for 1 hr followed by substrate addition and measured at 1 min interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1274675Inhibition of MMP24 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID182378Compound was tested for inhibition of Tumor Necrosis Factor production in rat at a peroral dose of 5 mg/kg1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID92730Inhibition of LPS-stimulated TNF-alpha release in human whole blood2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
AID1274677Inhibition of full length human recombinant MMP26 using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1574651Inhibition of MMP2 (unknown origin) preincubated for 1 hr followed by (QF)-24 substrate addition measured at 1 min time interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID107172Inhibitory activity against matrix metalloprotease-2 (MMP2)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID104711Inhibition of matrix metalloprotease-21999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
AID107358Activity against Matrix metalloprotease-3 (MMP-3).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID109578Inhibitory concentration against Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID215431Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID152805Inhibitory concentration required against shedding of TNF RII from stimulated PBMCs2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID109580Activity against Matrix metalloprotease-2 (MMP-2).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID107344Inhibitory potency against Matrix metalloprotease-2 (MMP-2)2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1274676Inhibition of MMP25 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID108177Inhibition of recombinant human matrix metalloprotease-9 (gelatinase B)2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
AID104554Inhibition of matrix metalloprotease-11999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
AID104708Inhibition of Coll-3 MMP-131999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID12008Bioavailability as oral Cmax in rats at 30 mins1999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID1607848Inhibition of MMP8 (unknown origin) using QF-24 as substrate preincubated for 1 hr followed by substrate addition and measured at 1 min interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1863882Inhibition of MMP-14 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1875282Inhibition of MMP9 in human U2OS cells by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID108749Inhibitory activity against MMP-1 (Matrix metalloprotease-1)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID107657Inhibition of human MMP-3.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID108894Inhibitory activity against matrix metalloprotease-1 (MMP1)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID104925In vitro inhibitory activity against matrix metalloprotease 2 isolated from human HT1080 fibrosarcoma cells induced with TNF1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1265276Inhibition of recombinant Teladorsagia circumcincta DPY-31 astacin domain expressed in Escherichia coli using Suc-Ala-Ala-Ala-pNA as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by microplate reader assay2015Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24
Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31.
AID182377Compound was tested for inhibition of Tumor Necrosis Factor production in rat at a peroral dose of 2.5 mg/kg1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID10716850 percent inhibition of human Matrix metalloprotease-2 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID210153TNF-alpha convertase activity following phorbol 12-myristate 13-acetate (PMA) stimulation of U937 cells1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID10876650 percent inhibition of human Matrix metalloprotease-1 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID108935In vitro inhibition of human MMP-1.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
AID220527Activity against deletion mutant of MT1-MMP lacking the transmembrane domain (deltaMT1)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID215604Inhibition of TNF(tumor necrosis factor) in human blood1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
AID104749Inhibition of Strom-1 MMP-31999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID107514Inhibitory activity against matrix metalloprotease-3 (MMP3)2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
AID152806Inhibitory concentration required against shedding of TNF-alpha from stimulated PBMCs2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID109417Inhibition of Matrix metalloprotease-13 (MMP-13) in fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID109377Inhibitory activity against human Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
AID1274673Inhibition of MMP16 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID10938250 percent inhibition of human Matrix metalloprotease-13 by the cleavage of fluorogenic peptide MCA-Pro-Leu-Gly-Leu-Dpa-ala-Arg-NH22000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
Synthesis and activity of selective MMP inhibitors with an aryl backbone.
AID104713Inhibition of Gel-A MMP-21999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID210150Inhibitory activity against tumor necrosis factor alpha (TNF-alpha) production in LPS-stimulated human PBMCs2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
AID109264Inhibition of Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID108176Inhibition of recombinant human matrix metalloprotease-92003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
AID152803Inhibitory concentration required against shedding of IL6-R from stimulated PBMCs2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID1274669Inhibition of recombinant human MMP10 catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID104556Inhibition of HFC MMP-11999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID12487Half life period after intravenous administration at 20 mpk in rats2001Bioorganic & medicinal chemistry letters, Sep-17, Volume: 11, Issue:18
Selective, orally active MMP inhibitors with an aryl backbone.
AID1863880Inhibition of MMP-12 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863881Inhibition of MMP-13 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID104912Inhibition of HNC MMP-81999Bioorganic & medicinal chemistry letters, Oct-04, Volume: 9, Issue:19
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
AID440472Half life in rat at 20 mg/kg, iv2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Hydroxamates: relationships between structure and plasma stability.
AID182376Compound was tested for inhibition of Tumor Necrosis Factor production in rat at a peroral dose of 10 mg/kg1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1274670Inhibition of MMP12 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID230243Ratio of Matrix metalloprotease-1 to that of Matrix metalloprotease-132001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
AID12993Oral bioavailability in monkey (dose 10 mg/kg)1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID184405Percent inhibition against adjuvant arthritis in rats tested in vivo at 10 mg/kg2001Bioorganic & medicinal chemistry letters, Jun-04, Volume: 11, Issue:11
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
AID12480Half life was measured in monkey at dose of 10 mg/kg by po administration1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1863878Inhibition of MMP-8 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1274667Inhibition of MMP7 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1274648Inhibition of MMP3 (unknown origin) catalytic domain using Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID107159Inhibition of Matrix metalloprotease-22001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID107654Inhibition of recombinant human matrix metalloprotease-32003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
AID107690Inhibition of matrix metalloprotease-7 (Matrilysin)1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1274672Inhibition of MMP15 (unknown origin) catalytic domain using MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH2 as substrate preincubated for 60 mins followed by substrate addition by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID107502Inhibition of Matrix metalloprotease-32001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID1235683Inhibition of ADAM17 in human A549 cells assessed as decrease in PMA-stimulated soluble TGFalpha level in cell supernatant at 10 uM preincubated for 1 hr followed by PMA stimulation measured after 1 hr by ELISA2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
AID1875280Inhibition of MMP1 in human U2OS cells at 1 umol/L by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID1863879Inhibition of MMP-9 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1875284Inhibition of MMP3 in human U2OS cells by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID104928In vitro inhibitory activity against human recombinant matrix metalloprotease 71998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1274709Inhibition of full length recombinant ADAMTS5 (unknown origin) expressed in insect Sf9 cells after 6 hrs by alkaline phosphatase-based assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1574654Inhibition of MMP13 (unknown origin) preincubated for 1 hr followed by (QF)-24 substrate addition measured at 1 min time interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID108758Inhibition of Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID108731Activity against Matrix metalloprotease-1 (MMP-1).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID107333In vitro selective inhibition against matrix metalloprotease-2 (MMP-2) using fluorimetric assay2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID107356Inhibition of matrix metalloprotease-3 (Stromelysin-1)1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1863874Inhibition of MMP-1 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1274708Inhibition of full length recombinant ADAMTS4 (unknown origin) expressed in insect Sf9 cells after 6 hrs by alkaline phosphatase-based assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
AID108162In vitro inhibition of human MMP-9.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
AID215597Inhibition of recombinant human tumor necrosis factor-alpha converting enzyme2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
AID11793Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
AID1607847Inhibition of MMP9 (unknown origin) using QF-24 as substrate preincubated for 1 hr followed by substrate addition and measured at 1 min interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.
AID1863876Inhibition of MMP-3 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1875281Inhibition of MMP13 in human U2OS cells by peptide microarray-based fluorescence assay2022Journal of natural products, 10-28, Volume: 85, Issue:10
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.
AID108932Inhibition of Recombinant human matrix metalloprotease-12003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
AID104707Inhibition of matrix metalloprotease-131999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1235680Inhibition of ADAM10 in human A549 cells assessed as inhibition of betacellulin shedding at 10 uM after 1 hr by ELISA2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.
AID1574655Inhibition of MMP7 (unknown origin) preincubated for 1 hr followed by (QF)-24 substrate addition measured at 1 min time interval for 1 hr by fluorescence assay2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2009The Journal of biological chemistry, Sep-04, Volume: 284, Issue:36
Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (207)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's41 (19.81)18.2507
2000's107 (51.69)29.6817
2010's37 (17.87)24.3611
2020's22 (10.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.90 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index49.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (13.02%)5.53%
Reviews45 (20.93%)6.00%
Case Studies1 (0.47%)4.05%
Observational0 (0.00%)0.25%
Other141 (65.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy [NCT00003010]Phase 3334 participants (Anticipated)Interventional1997-12-02Completed
Phase I Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Marimastat in Patients With Disabling Malformations and No Other Treatment Options [NCT00261391]Phase 19 participants Interventional2000-10-31Completed
A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER [NCT00002911]Phase 30 participants Interventional1996-12-31Completed
A Phase III Study of Marimastat in Patients With Small Cell Lung Cancer Following a Response to First Line Chemotherapy [NCT00003011]Phase 3555 participants (Actual)Interventional1997-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]